ArticleLeukemia2015
Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation.
Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06125483 (A Clinical Study of Low-dose Total Body Irradiation and Fludarabine/Busulfan/Melphalan as a Conditioning Regimen for Secondary Umbilical Cord Blood Transplantation in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT), which is not on this map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Study of Low-dose Total Body Irradiation and Fludarabine/Busulfan/Melphalan as a Conditioning Regimen for Secondary Umbilical Cord Blood Transplantation in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.
- Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.Nature communications · 2021Pooled it
- Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.Blood advances · 2019Trial
- Second alternative-donor haploidentical stem cell transplantation enhances survival in patients with myeloid malignancies complicated by posttransplant human leukocyte antigen loss relapse.Bone marrow transplantation · 2026Article
- Late outcomes after posttransplant cyclophosphamide-based GVHD prophylaxis in patients with AML: an ALWP-EBMT study.Blood neoplasia · 2026Article
- Biomarkers and advances in AML-MRC: from bench to bedside.Annals of hematology · 2026Review
- Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation.Frontiers in immunology · 2026Review
- Analysis of HLA genotype in the recipients' different tissues after haploidentical hematopoietic stem cell transplantation.Frontiers in immunology · 2026Article
- Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease.Frontiers in oncology · 2026Review
- HLA loss-mediated immune escape of acute leukemias in pediatric patients post haploidentical transplantation.Bone marrow transplantation · 2025Article
- CAR-T cell therapy for cancer: current challenges and future directions.Signal transduction and targeted therapy · 2025Review
- Immune Escape of Acute Myeloid Leukemia after Transplantation.Blood cancer discovery · 2025Review
- Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.Bone marrow transplantation · 2025Article
- Long-Term Donor Chimerism Monitoring for Relapse Risk Assessment After Pediatric Allo-HSCT.The application of clinical genetics · 2025Article
- Maintenance strategies for relapse prevention and treatment.Hematology. American Society of Hematology. Education Program · 2024Review
- Biology of post-transplant relapse: actionable features.Hematology. American Society of Hematology. Education Program · 2024Review
- Review
- Single-cell analysis of the survival mechanisms of fratricidal CAR-T targeting of T cell malignancies.Molecular therapy. Nucleic acids · 2024Article
- Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients.Blood cancer journal · 2024Article
- HLA Haplotypes and Relapse After Hematopoietic Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.Frontiers in immunology · 2024Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomic loss of the mismatched human leukocyte antigen (HLA) is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Here we first evaluated its incidence, risk factors and outcome in 233 consecutive transplants from partially HLA-mismatched related and unrelated donors (MMRD and MMUD, respectively). We documented 84 relapses, 23 of which with HLA loss. All the HLA loss relapses occurred after MMRD HSCT, and 20/23 in patients with acute myeloid leukemia. Upon MMRD HSCT, HLA loss variants accounted for 33% of the relapses (23/69), occurring later than their 'classical' counterparts (median: 307 vs 88 days, P<0.0001). Active disease at HSCT increased the risk of HLA loss (hazard ratio (HR): 10.16; confidence interval (CI): 2.65-38.92; P=0.001), whereas older patient ages had a protective role (HR: 0.16; CI: 0.05-0.46; P=0.001). A weaker association with HLA loss was observed for graft T-cell dose and occurrence of chronic graft-versus-host disease. Outcome after 'classical' and HLA loss relapses was similarly poor, and second transplantation from a different donor appeared to provide a slight advantage for survival. In conclusion, HLA loss is a frequent mechanism of evasion from T-cell alloreactivity and relapse in patients with myeloid malignancies transplanted from MMRDs, warranting routine screening in this transplantation setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.